Intraperitoneal and Intravenous Paclitaxel Chemotherapy With Oral Capecitabine for Gastric Adenocarcinoma With Peritoneal Carcinomatosis

National Cancer Institute (NCI) (NIH)
Overall Status
Recruiting ID

Study Details

Study Description

Brief Summary


Three-fourths of people diagnosed with gastric cancer will die from it. Researchers want to see if giving cancer drugs in a new way can help people live longer and delay the time it takes for the cancer to grow.


To find a better way to treat advanced stomach cancer.


People ages 18 and older with stomach cancer that has spread throughout their belly.

Participants will be screened with:

Medical history

Physical exam

Blood, urine, and heart tests


Cancer sample: If they do not have one, they will have a biopsy.

Tests of performance of normal activities

Dietary assessment

Participants will have a laparoscopy. Small cuts are made into their abdomen. A thin camera with a light is inserted. Small instruments are used to take biopsies. This will be repeated during the study to monitor the cancer. During the first laparoscopy, a port with a catheter attached will be put into the abdomen.

Participants may also have an endoscopy: A thin tube with a camera is inserted through the mouth and into the stomach. The tube collects samples to monitor the cancer.

Participants will get paclitaxel every 3 weeks through the abdominal port and through a small plastic tube in an arm vein. They will also take capecitabine by mouth twice daily for the first 15 days of a 21-day cycle.

After participants finish 3 cycles, they will have scans to see how they are doing. They may get another course of therapy.

Participants will have visits every 3 weeks during treatment. Then they will have follow-up visits for 5 years. Then they will keep in touch with researchers for the rest of their life.

Condition or Disease Intervention/Treatment Phase
Phase 2

Detailed Description

  • An estimated 28,000 cases of gastric adenocarcinoma are diagnosed annually in the U.S.

  • Peritoneal metastasis is a common finding at diagnosis, making curative surgical resection possible in an estimated 25% of patients.

  • Systemic chemotherapy is the recommended treatment for patients with metastatic gastric cancer to the peritoneal cavity, however selective use of cytoreductive surgery and intraperitoneal chemotherapy has been associated with improved overall survival.

  • Multiple chemotherapeutic agents and delivery systems have been described for intraperitoneal therapy, but no standard regimen exists.


-Determine the intraperitoneal progression free survival (iPFS) in patients with peritoneal metastases from gastric cancer after repeated intraperitoneal chemotherapeutic infusion (IPC) and systemic paclitaxel administration with concomitant capecitabine therapy.

  • Histologically confirmed adenocarcinoma of the stomach.

  • Radiographic evidence of peritoneal carcinomatosis and/or sub-radiographic evidence of peritoneal carcinomatosis found at staging laparoscopy.

  • Medically fit for systemic chemotherapy and intraperitoneal chemotherapy.

  • Men and women age greater than or equal to 18 years.

  • Phase II, nonrandomized, open label study.

  • Patients will enroll in two cohorts: those with prior systemic chemotherapy and those who are treatment naive.

  • Patients undergo staging laparoscopy and placement of peritoneal access port.

  • Intraperitoneal paclitaxel (60 mg/m2 weekly), intravenous paclitaxel (80 mg/m2 weekly), and capecitabine (825 mg/m2 twice daily for 14 days of each cycle) for 12 weeks.

  • Treatment response will be assessed with imaging and laparoscopy.

  • It is expected that 16-20 patients per year for total 4 years will be enrolled. The accrual ceiling is set at 74 patients.

Study Design

Study Type:
Anticipated Enrollment :
74 participants
Intervention Model:
Single Group Assignment
None (Open Label)
Primary Purpose:
Official Title:
A Phase II Study of Intraperitoneal and Intravenous Paclitaxel Chemotherapy With Oral Capecitabine for Gastric Adenocarcinoma With Peritoneal Carcinomatosis
Actual Study Start Date :
Jun 9, 2020
Anticipated Primary Completion Date :
May 30, 2026
Anticipated Study Completion Date :
Jan 30, 2027

Arms and Interventions

Arm Intervention/Treatment
Experimental: 1/ Arm1

IP and IV paclitaxel administration with concomitant oral capecitabine

Drug: Paclitaxel
Paclitaxel (IP and IV), Day 1 of each 3-week cycle: Paclitaxel IP - Intraperitoneal paclitaxel (60 mg/m2) will be diluted in 500 mL of 0.9% NS, to be infused as rapidly as tolerated once per 3-week cycle on Day 1. Paclitaxel IV - Intravenous paclitaxel (80 mg/m2) will be administered concomitantly over 3 hours, diluted in 100 to 250 ml of 0.9% NS once per 3-week cycle on Day 1.

Drug: Capecitabine
Day 1-15 of each 3-week cycle: oral capecitabine (825 mg/m2) to be taken twice a day starting the evening of Day 1 of each cycle until the morning of Day 15, followed by a 7-day rest period during each 3-week cycle.

Device: BardPort Titanium Implanted Port with Peritoneal Catheter
After peritoneal chemo infusion port is placed (Days 1-3, as dictated by clinical status), patients will begin intraperitoneal paclitaxel and intravenous paclitaxel (Day 1) followed by oral capecitabine on the evening of Day 1 to the morning of Day 15.

Outcome Measures

Primary Outcome Measures

  1. to determine progression free survival (PFS) in patients with peritoneal metastases from gastric cancer after repeated intraperitoneal chemotherapeutic infusion (IPC) and systemic paclitaxel administration with concomitant capecitabine therapy [after 1 course (3 treatment cycles; 9 weeks)]

    to determine if the response rate (median amount of time) is better than that of the response rate based on historical controls

Secondary Outcome Measures

  1. overall survival [death]

    median amount of time subject survives

  2. morbidity of this treatment strategy [4 years]

    frequency of complications and adverse events

  3. intra-peritoneal progression free survival (iPFS) [at intra-peritoneal progression]

    median amount of time subject survives without intra-peritoneal disease progression

  4. frequency of objective histopathologic response to therapy [at end of each course (3 treatment cycles; 9 weeks)]

    graded tumor biopsy

  5. distant (extra-peritoneal) disease free survival [at extra-peritoneal progression]

    median amount of time subject survives without extra-peritoneal disease progression

Eligibility Criteria


Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
Accepts Healthy Volunteers:


  1. Patients must have histologically or cytologically confirmed gastric adenocarcinoma, including Siewert III gastroesophageal junction adenocarcinoma, confirmed by the NCI Laboratory of Pathology, and have provided a block or unstained slides of primary or

metastatic tumor tissue or newly obtained fresh biopsy of a tumor lesion in case archival tissue sample is not available.

  1. Patients may be treatment na(SqrRoot) ve or have received systemic chemotherapy prior to enrollment:
  • Trastuzumab allowed as prior treatment for HER2/neu over-expressing cancers as clinically indicated.

  • Last dose of chemotherapy at least 2 weeks prior to enrollment with recovery to Grade 1 from chemotherapy-related toxicities.

  1. Radiographic evidence of peritoneal carcinomatosis and/or sub-radiographic evidence of peritoneal carcinomatosis found at staging laparoscopy.

  2. Age >=18 years. Children under the age of 18 will not participate in this study as gastric cancer is rare in this population.

  3. ECOG performance status <=1

  4. Patients must have normal organ and marrow function as defined below:

hemoglobin >=8.0 g/dL

absolute neutrophil count >=1,000/mcL

platelets >=100,000/mcL

total bilirubin <=1.5 X institutional upper limit of normal

AST(SGOT)/ALT(SGPT) <=2.5 X institutional upper limit of normal

creatinine <1.5 mg/dl


creatinine clearance >=60 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal.

  1. Physiologically able to undergo laparoscopy and systemic chemotherapy.

  2. Ability of subject to understand and the willingness to sign a written informed consent document.

  3. Previous exploratory laparotomy or laparoscopy with tissue biopsy or peritoneal lavage is permitted.

  4. Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study treatment. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.

  5. Patients must be co-enrolled in protocol 13C0176 (NCT01915225) and 17C0044 (NCT03027427) for sample collection.

  6. HIV-positive patients may be considered for this study only after consultation with a NIAID physician.

  1. Patients who are receiving any other investigational agents.

  2. Previous cytoreductive surgery or intraperitoneal chemotherapy.

  3. Disseminated extra-peritoneal or solid organ metastases:

  • Excludes greater omentum and ovarian metastases.

  • Radiographic signs or clinical symptoms consistent with malignant bowel obstruction.

  1. History of allergic reactions attributed to compounds of similar chemical or biologic composition to Paclitaxel or Capecitabine or other agents used in study.

  2. Previous treatment with paclitaxel or nab-paclitaxel resulting in progression of disease.

  3. Existing peripheral neuropathy, Grade 3 or greater.

  4. Past medical history of dihydropyrimidine dehydrogenase deficiency.

  5. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.

  6. Pregnant women are excluded because paclitaxel and capecitabine can cause fetal harm when administered to pregnant women. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with paclitaxel and capecitabine, breastfeeding should be discontinued if the mother is treated with paclitaxel and capecitabine.

Contacts and Locations


Site City State Country Postal Code
1 National Institutes of Health Clinical Center Bethesda Maryland United States 20892

Sponsors and Collaborators

  • National Cancer Institute (NCI)


  • Principal Investigator: Jeremy L Davis, M.D., National Cancer Institute (NCI)

Study Documents (Full-Text)

None provided.

More Information

Additional Information:


None provided.
Responsible Party:
National Cancer Institute (NCI) Identifier:
Other Study ID Numbers:
  • 190129
  • 19-C-0129
First Posted:
Jul 26, 2019
Last Update Posted:
Jul 20, 2022
Last Verified:
Jul 18, 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD:
Studies a U.S. FDA-regulated Drug Product:
Studies a U.S. FDA-regulated Device Product:
Keywords provided by National Cancer Institute (NCI)
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 20, 2022